Full metadata record
DC FieldValueLanguage
dc.creatorThavendiranathan, P. (Paaladinesh)-
dc.creatorZhang, L. (Lili)-
dc.creatorZafar, A. (Amna)-
dc.creatorDrobni, Z. (Zsofia)-
dc.creatorMahmood, S.S. (Syed S.)-
dc.creatorCabral, M. (Marcella)-
dc.creatorAwadalla, M. (Magid)-
dc.creatorNohria, A. (Anju)-
dc.creatorZlotoff, D.A. (Daniel A.)-
dc.creatorThuny, F. (Franck)-
dc.creatorHeinzerling, L.M. (Lucie M.)-
dc.creatorBarac, A. (Ana)-
dc.creatorSullivan, R. (Ryan)-
dc.creatorChen, C.L. (Carol L.)-
dc.creatorGupta, D. (Dipti)-
dc.creatorKirchberger, M.C. (Michael C.)-
dc.creatorHartmann, S.E. (Sarah E.)-
dc.creatorWeinsaft, J.W. (Jonathan W.)-
dc.creatorGilman, H.K. (Hannah K.)-
dc.creatorRizvi, M.A. (Muhammad A.)-
dc.creatorKovacina, B. (Bojan)-
dc.creatorMichel, C. (Caroline)-
dc.creatorSahni, G. (Gagan)-
dc.creatorGonzález-Mansilla, A. (Ana)-
dc.creatorCalles, A. (Antonio)-
dc.creatorFernandez-Aviles, F. (Francisco)-
dc.creatorMahmoudi, M. (Michael)-
dc.creatorReynolds, K.L. (Kerry L.)-
dc.creatorGanatra, S. (Sarju)-
dc.creatorGavira, J.J. (Juan José)-
dc.creatorSalterain-González, N. (Nahikari)-
dc.creatorGarcia-de-Yebenes, M. (Manuel)-
dc.creatorKwong, R.Y. (Raymond Y.)-
dc.creatorJerosch-Herold, M. (M.)-
dc.creatorCoelho-Filho, O.R. (Otavio R.)-
dc.creatorAfilalo, J. (Jonathan)-
dc.creatorZatarain-Nicolás, E. (Eduardo)-
dc.creatorBaksi, A.J. (A. John)-
dc.creatorWintersperger, B.J. (B. J.)-
dc.creatorCalvillo-Arguelles, O. (Oscar)-
dc.creatorEderhy, S. (Stephane)-
dc.creatorYang, E.H. (Eric H.)-
dc.creatorLyon, A.R. (Alexander R.)-
dc.creatorFradley, M.G. (Michael G.)-
dc.creatorNeilan, T.G. (T.G.)-
dc.identifier.citationThavendiranathan, P. (Paaladinesh); Zhang, L. (Lili); Zafar, A. (Amna); et al. "Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor–associated myocarditis". Journal of the American College of Cardiology. 77 (12), 2021, 1503 - 1516es_ES
dc.description.abstractBACKGROUND Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited. OBJECTIVES This study sought to assess the value of CMR T1 and T2 mapping in patients with ICI myocarditis. METHODS In this retrospective study from an international registry of patients with ICI myocarditis, clinical and CMR findings (including T1 and T2 maps) were collected. Abnormal T1 and T2 were defined as 2 SD above site (vendor/field strength specific) reference values and a z-score was calculated for each patient. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. RESULTS Of 136 patients with ICI myocarditis with a CMR, 86 (63%) had T1 maps and 79 (58%) also had T2 maps. Among the 86 patients (66.3 13.1 years of age), 36 (41.9%) had a left ventricular ejection fraction <55%. Across all patients, mean z-scores for T1 and T2 values were 2.9 1.9 (p < 0.001) and 2.2 2.1 (p < 0.001), respectively. On Siemens 1.5-T scanner (n ¼ 67), native T1 (1,079.0 55.5 ms vs. 1,000.3 22.1 ms; p < 0.001) and T2 (56.2 4.9 ms vs. 49.8 2.2 ms; p < 0.001) values were elevated compared with reference values. Abnormal T1 and T2 values were seen in 78% and 43% of the patients, respectively. Applying the modified Lake Louise Criteria, 95% met the nonischemic myocardial injury criteria and 53% met the myocardial edema criteria. Native T1 values had excellent discriminatory value for subsequent MACE, with an area under the curve of 0.91 (95% confidence interval: 0.84 to 0.98). Native T1 values (for every 1-unit increase in z-score, hazard ratio: 1.44; 95% confidence interval: 1.12 to 1.84; p ¼ 0.004) but not T2 values were independently associated with subsequent MACE. CONCLUSIONS The use of T1 mapping and application of the modified Lake Louise Criteria provides important diagnostic value, and T1 mapping provides prognostic value in patients with ICI myocarditis. (J Am Coll Cardiol 2021;77:1503–16) © 2021 by the American College of Cardiology Foundation.es_ES
dc.description.sponsorshipDr. Thavendiranathan was supported, in part, through the Canadian Institutes of Health Research New Investigator Award (FRN 147814) and a Canada Research Chair in Cardio-Oncology. This work is supported by the New York Academy of Medicine’s Glorney-Raisbeck Award to Dr. Mahmood. Dr. Sullivan was supported, in part, through the National Institutes of Health (NIH)/National Cancer Institute (RO1CA229851, UH2CA207355, RO1CA193970). Dr. C.L. Chen, and Dr. D. Gupta were supported, in part, through the NIH/National Cancer Institute P30CA008748. Dr. Neilan was supported, in part, through the Kohlberg Foundation, the NIH/National Heart, Lung, and Blood Institute (RO1HL130539, RO1HL137562, and K24HL150238), and the NIH/Harvard Center for AIDS Research (P30 AI060354). Dr. Thavendiranathan has received Speakers Bureau fees from Amgen, Takeda, and BI. Dr. Mahmood has received consulting fees from OMR Globus, Alpha Detail, and Opinion Research Team. Dr. Nohria has received research grant support from Amgen; and has served a consultant for Takeda Oncology. Dr. Heinzerling has received consulting, advisory board, and speaker fees from MSD, BMS, Roche, Novartis, Amgen, and Curevac. Dr. Sullivan has served as a consultant for Merck and Novartis. Dr. Groarke has received research support from Amgen. Dr. Neilan has received advisory fees from Parexel, BMS, H3 Biomedicine, AbbVie, and Intrinsic Imaging. Dr. Neilan has received grant support from AstraZeneca. Dr. Wintersperger has received research support and speaker honoraria from Siemens Healthineers (the University Health Network has a master research agreement with Siemens Healthineers); and is an inventor of the IG fitting method owned by the University Health Network (US10314548B2). Dr. Yang has received research funding from CSL Behring. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.es_ES
dc.publisherElsevier BVes_ES
dc.subjectCardiovascular magnetic resonancees_ES
dc.subjectImmune checkpoint inhibitorses_ES
dc.subjectLake Louise Criteriaes_ES
dc.subjectMajor adverse cardiovascular eventes_ES
dc.subjectT1 mappinges_ES
dc.subjectT2 mappinges_ES
dc.titleMyocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor–associated myocarditises_ES
dadun.citation.publicationNameJournal of the American College of Cardiologyes_ES

Files in This Item:
1.51 MB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.